2019 Insurance Manufacturing Patients 
Physician's Weekly
JUNE 19, 2025
In this first installment of a two-part series, “An Arm and a Leg” shares lessons from Bob’s experience navigating a maze of pharmacies and insurance companies to get his daughter the medicine she needs. Bob’s journey here begins in 2019 — the first day of high school for his daughter, Mary. That happens a lot.
FDA Law Blog
JANUARY 11, 2022
The Court, however, would not dismiss similar allegations as applied to health insurer. Specifically, Amarin alleged that Hikma’s label “teaches CV risk reduction” due to “a notice regarding side effects for patients with CV disease” and an absence of a statement that the generic “should not be used for the CV indication….”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law Blog
JANUARY 11, 2022
The Court, however, would not dismiss similar allegations as applied to health insurer. Specifically, Amarin alleged that Hikma’s label “teaches CV risk reduction” due to “a notice regarding side effects for patients with CV disease” and an absence of a statement that the generic “should not be used for the CV indication….”
FDA Law Blog
SEPTEMBER 8, 2022
Wasserstein — Three patient advocate groups have sued the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS), challenging HHS’s 2020 Notice of Benefits and Payment Parameters (NBPP) rule. The patient, on the other hand, is no closer to meeting their deductible than before.
Expert insights. Personalized for you.
52 
Let's personalize your content